$1.66
19.42% yesterday
Nasdaq, Sep 23, 10:18 pm CET
ISIN
US67577C1053
Symbol
OCGN

Ocugen Inc Stock price

$1.66
+0.62 59.62% 1M
+1.02 160.43% 6M
+0.86 106.21% YTD
+0.62 59.62% 1Y
-0.13 7.26% 3Y
+1.35 435.48% 5Y
-296.54 99.44% 10Y
-703.34 99.76% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
+0.27 19.42%
ISIN
US67577C1053
Symbol
OCGN
Industry

Key metrics

Basic
Market capitalization
$518.4m
Enterprise Value
$519.4m
Net debt
$1.0m
Cash
$27.0m
Shares outstanding
292.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
109.1 | 145.1
EV/Sales
109.4 | 145.4
EV/FCF
negative
P/B
170.0
Financial Health
Equity Ratio
35.9%
Return on Equity
-182.4%
ROCE
-155.6%
ROIC
-
Debt/Equity
9.2
Financials (TTM | estimate)
Revenue
$4.8m | $3.6m
EBITDA
$-52.3m | -
EBIT
$-55.4m | $-59.8m
Net Income
$-56.9m | $-67.6m
Free Cash Flow
$-52.3m
Growth (TTM | estimate)
Revenue
-48.4% | -12.0%
EBITDA
16.7% | -
EBIT
13.4% | -9.3%
Net Income
9.3% | -25.0%
Free Cash Flow
4.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,101.0% | -
EBIT
-1,165.1%
Net
-1,197.7% | -1,891.3%
Free Cash Flow
-1,100.2%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
17.7%
Employees
95
Rev per Employee
$40.0k
Show more

Is Ocugen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Ocugen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Ocugen Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Ocugen Inc forecast:

Buy
90%
Hold
10%

Financial data from Ocugen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4.75 4.75
48% 48%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 26 26
26% 26%
543%
- Research and Development Expense 34 34
11% 11%
723%
-52 -52
17% 17%
-1,102%
- Depreciation and Amortization 3.05 3.05
175% 175%
64%
EBIT (Operating Income) EBIT -55 -55
13% 13%
-1,166%
Net Profit -57 -57
9% 9%
-1,199%

In millions USD.

Don't miss a Thing! We will send you all news about Ocugen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocugen Inc Stock News

Positive
Seeking Alpha
about 20 hours ago
Ocugen (OCGN) is a clinical-stage biotech focused on modifier gene therapies for inherited retinal diseases, with key catalysts expected by 2026. OCGN's pipeline includes OCU400 (RP/LCA), OCU410ST (Stargardt disease), and OCU410 (Geographic Atrophy), all addressing large unmet needs with no current cures. Recent FDA designations, strategic partnerships, and successful financings reduce dilution...
Positive
The Motley Fool
8 days ago
On Monday, investors clearly saw excellent value in the stock of Ocugen (OCGN 12.15%), a biotech that concentrates on treatments for eye disorders. They traded the company's shares up by more than 12%, on the back of a fresh licensing agreement signed with a peer in Asia.
Neutral
GlobeNewsWire
9 days ago
MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd., (“Kwangdong”) one of the leading pharmaceutical companies in Korea, for the exclusive Korean rights to OCU400—Ocugen's novel modifier ge...
More Ocugen Inc News

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Head office United States
CEO Shankar Musunuri
Employees 95
Founded 2013
Website ocugen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today